These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30869167)

  • 1. A post hoc analysis of the long-term safety and efficacy of perampanel in Asian patients with epilepsy.
    Inoue Y; Kaneko S; Hsieh PF; Meshram C; Lee SA; Aziz ZA; Nabangchang C; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():60-67. PubMed ID: 30869167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations.
    Nishida T; Lee SK; Wu T; Tiamkao S; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():47-59. PubMed ID: 30869168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy.
    Tsai JJ; Ikeda A; Hong SB; Likasitwattanakul S; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():37-46. PubMed ID: 30869165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
    Steinhoff BJ; Patten A; Williams B; Malhotra M
    Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
    Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
    CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of Phase II and Phase III double-blind and open-label extension studies in India.
    Mehndiratta MM; Gulhane M; Jabeen SA; Patten A; Dash A; Malhotra M
    Epilepsia Open; 2021 Mar; 6(1):90-101. PubMed ID: 33681652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies.
    Piña-Garza JE; Villanueva V; Rosenfeld W; Yoshinaga H; Patten A; Malhotra M
    Epilepsy Behav; 2022 Oct; 135():108901. PubMed ID: 36122531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
    Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies.
    Rektor I; Krauss GL; Inoue Y; Kaneko S; Williams B; Patten A; Malhotra M; Laurenza A; Wechsler RT
    Epilepsia; 2020 Jul; 61(7):1491-1502. PubMed ID: 32645213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multivariable prediction model of a major treatment response for focal-onset seizures: A post-hoc analysis of Phase III trials of perampanel.
    Krauss GL; Ben-Menachem E; Wechsler RT; Patten A; Williams B; Laurenza A; Malhotra M
    Epilepsy Res; 2021 Aug; 174():106649. PubMed ID: 34022524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of adjunctive perampanel in patients from the Asia-Pacific region with refractory focal-onset seizures in Study 335 open-label extension.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Malhotra M; Patten A; Kaneko S
    Epilepsia Open; 2024 Apr; 9(2):501-512. PubMed ID: 37867420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy.
    Maguire M; Ben-Menachem E; Patten A; Malhotra M; Ngo LY
    Epilepsy Behav; 2022 Jan; 126():108483. PubMed ID: 34953337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.
    Resnick T; Patten A; Ngo LY; Malhotra M
    Epilepsy Behav; 2022 Mar; 128():108528. PubMed ID: 35078116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
    Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
    Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508.
    Ravat S; Rohatgi A; Kulkarni R; Jabeen SA; Patil B; Dash A; Malhotra M
    Epilepsia Open; 2024 Jun; 9(3):940-950. PubMed ID: 38124551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
    Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
    Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to <12 years) with inadequately controlled focal-onset seizures: Japanese subgroup analysis.
    Omatsu H; Watanabe T; Kira R; Ishiba K; Patten A; Takase T; Ngo LY
    Seizure; 2023 Aug; 110():109-116. PubMed ID: 37336055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
    Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of primary generalized tonic-clonic seizures.
    Kerr WT; Ngo LY; Zhu L; Patten A; Cheng JY; Reddy AS; French JA
    Epilepsia; 2024 Aug; 65(8):2412-2422. PubMed ID: 38864472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.